BioAge Labs, Inc. Income Statement
BIOA / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
BioAge Labs, Inc. reported $9M in revenue and $81M in net loss for FY2025. Its profit margin was -896.1% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $9.0M | - | - |
| SG&A Expense | $27.8M | $19.2M | $14.5M |
| R&D Expense | $74.0M | $59.0M | $33.9M |
| Operating Income | -$92.8M | -$78.2M | -$48.4M |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$80.6M | -$71.1M | -$63.9M |
| EPS (Basic) | -$6.63 | -$6.63 | -$38.17 |
| EPS (Diluted) | -$6.63 | -$6.63 | -$38.17 |
| Shares Outstanding | 35.9M | 10.7M | 1.7M |
| Operating Margin | -1031.5% | - | - |
| Profit Margin | -896.1% | - | - |